Freeman Technology relocates to larger premises
New global hq includes manufacturing and office space and an applications laboratory
The new 6,000ft2 global headquarters has been equipped to meet the company’s requirements for manufacturing and office space, as well as housing a 300ft2 applications laboratory.
The move into this ultra-modern facility comes just over a decade after the company launched its first powder testing instrument.
Operations director Tim Freeman said: ‘I am delighted to be able to report that demand for the FT4 powder rheometer continues to grow around the world and across powder processing industries.
‘As a result, not only are we building more systems, but we are also continuing to invest in r&d and applications development.
‘This new facility will enable us to scale up our manufacturing and r&d operations and continue to expand well into the future.’
He said the new laboratory would enable the company to carry out additional in-house research into powder behaviour and processing and provide more extensive applications support for customers.
Freeman Technology has enjoyed a continued period of growth and success. This year the company has not only added to its UK-based team but also expanded its global distribution network, with new partnerships covering Japan, India, Singapore, Malaysia, Thailand and Taiwan.
You may also like
Finance
![Ofichem acquires US drug substance CDMO Kinentia Biosciences to expand transatlantic network]()
Ofichem acquires US drug substance CDMO Kinentia Biosciences to expand transatlantic network
Read moreThe company has agreed to acquire New York-based Kinentia Biosciences, expanding its US presence and combining Kinentia’s early-stage development expertise with Ofichem’s European drug substance development and GMP manufacturing capabilities
Trending Articles
You may also like
Finance
![Ofichem acquires US drug substance CDMO Kinentia Biosciences to expand transatlantic network]()
Ofichem acquires US drug substance CDMO Kinentia Biosciences to expand transatlantic network
The company has agreed to acquire New York-based Kinentia Biosciences, expanding its US presence and combining Kinentia’s early-stage development expertise with Ofichem’s European drug substance development and GMP manufacturing capabilities
Manufacturing
![Patented device reinvents Solid Phase Extraction]()
Patented device reinvents Solid Phase Extraction
Biotech Fluidics announce SPEedy - a device that provides an effortless way to perform Solid Phase Extraction (SPE) sample preparation procedures without need of an external vacuum and compatible with any adsorption chemistry or eluent composition
Manufacturing
![Orano Med inaugurates Europe's first industrial-scale lead-212 radioligand therapy facility]()
Orano Med inaugurates Europe's first industrial-scale lead-212 radioligand therapy facility
The €29m ATLab site will target up to 10,000 doses annually and its two-hour proximity to major European airports meets the critical 24-hour production-to-administration window imposed by lead-212's 10.6-hour half-life
Manufacturing
![Catalent launches ten-month gene-to-drug substance programme for complex biologics]()
Catalent launches ten-month gene-to-drug substance programme for complex biologics
The accelerated pathway extends the CDMO's Rapid Antibody framework to bispecifics and next-generation formats — targeting master cell bank release by month seven and bulk drug substance lot release by month ten
Design & Build
![Sterling Pharma Solutions doubles ADC manufacturing capacity at Deeside with new GMP suite]()
Sterling Pharma Solutions doubles ADC manufacturing capacity at Deeside with new GMP suite
The multi-million-pound expansion adds a 1400 sqft Grade C cleanroom, OEB5 containment handling and a 3400 sqft analytical laboratory — extending Sterling's bioconjugation capability from development through to Phase III and commercial scale